Sivia Capital Partners LLC Acquires New Stake in Medpace Holdings, Inc. $MEDP

Key Points

• Sivia Capital Partners LLC acquired 944 shares of Medpace Holdings, Inc. worth approximately $296,000 in the second quarter, as reported in their recent 13F filing.
• Medpace's stock has shown a 14.2% increase in revenue year-over-year, reporting $603.31 million in quarterly revenue against analysts' expectations of $537.70 million.
• Insider selling has occurred, with the General Counsel and CFO collectively selling 15,000 shares totaling over $6.8 million, indicating a significant reduction in their ownership positions.

Sivia Capital Partners LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 944 shares of the company's stock, valued at approximately $296,000.

A number of other large investors have also modified their holdings of the business. Mawer Investment Management Ltd. acquired a new stake in shares of Medpace during the first quarter worth about $212,131,000. Vulcan Value Partners LLC lifted its holdings in shares of Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock worth $99,159,000 after purchasing an additional 224,578 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock worth $37,009,000 after purchasing an additional 105,807 shares during the period. Invesco Ltd. lifted its holdings in shares of Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after purchasing an additional 102,015 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Medpace by 41,658.9% during the first quarter. GAMMA Investing LLC now owns 93,540 shares of the company's stock worth $28,501,000 after purchasing an additional 93,316 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This represents a 22.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the completion of the transaction, the chief executive officer directly owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 161,266 shares of company stock worth $74,111,427. Insiders own 20.30% of the company's stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded up $0.80 during midday trading on Monday, reaching $499.40. 35,127 shares of the company's stock traded hands, compared to its average volume of 438,936. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55. The company has a market cap of $14.03 billion, a P/E ratio of 37.13, a PEG ratio of 3.14 and a beta of 1.44. The company has a fifty day simple moving average of $446.89 and a two-hundred day simple moving average of $355.45.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter last year, the firm posted $2.75 EPS. The business's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on MEDP shares. Truist Financial lifted their target price on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Barclays boosted their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Robert W. Baird boosted their price target on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Medpace has a consensus rating of "Reduce" and an average target price of $422.27.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.